Share on LinkedInShare on LinkedIn

ARTICLE · 08 OCTOBER 2025

Spotlight On Upcoming Oral Arguments – October 2025

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

The following arguments will be available live to the public, both in-person and through online audio streaming. Access information will be available by 9 AM ET each day of argument at: https://cafc.uscourts.gov/home/oral-argument/listen-to-oral-arguments/.

United StatesIntellectual Property

The following arguments will be available live to the public, both in-person and through online audio streaming. Access information will be available by 9 AM ET each day of argument at: https://cafc.uscourts.gov/home/oral-argument/listen-to-oral-arguments/.

Tuesday, October 7, 2025, 10:00 A.M.

Regenxbio Inc. v. Sarepta Therapeutics, Inc., No. 2024-1408, Boston, MA, Panel C

This appeal arises from the district court's grant of summary judgment finding that Regenxbio's U.S. Patent No. 10,526,617 was invalid for claiming patent-ineligible subject matter under 35 U.S.C. § 101. The '617 patent claims a host cell containing a recombinant nucleic acid molecule, which is a combination of a naturally occurring adeno-associated virus (AAV) sequence and a non-AAV sequence. The district court found that the claimed host cells are not "markedly different" from their naturally occurring components, and that they are directed to a natural product without an inventive concept

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from